{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:58:48Z","timestamp":1787961528168,"version":"build-2784847793"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40262-020-00891-1","type":"journal-article","created":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T01:02:47Z","timestamp":1587171767000},"page":"659-669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-9248","authenticated-orcid":false,"given":"Cornelis","family":"Smit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariska Y. M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0571-7492","authenticated-orcid":false,"given":"John N.","family":"van den Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9893-4415","authenticated-orcid":false,"given":"Catherijne A. J.","family":"Knibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"key":"891_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237","author":"X Yao","year":"2020","unstructured":"Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa237.","journal-title":"Clin Infect Dis"},{"key":"891_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269\u201371.","journal-title":"Cell Res"},{"key":"891_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72\u20133.","journal-title":"Biosci Trends"},{"key":"891_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1743-422X-2-69","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.","journal-title":"Virol J"},{"key":"891_CR5","doi-asserted-by":"publisher","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","volume":"177","author":"F Touret","year":"2020","unstructured":"Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;177:104762.","journal-title":"Antiviral Res"},{"key":"891_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/infdis\/155.2.192","volume":"155","author":"NJ White","year":"1987","unstructured":"White NJ, Watt G, Bergqvist Y, Njelesani EK. Parenteral chloroquine for treating falciparum malaria. J Infect Dis. 1987;155:192\u2013201.","journal-title":"J Infect Dis"},{"key":"891_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1365-2125.1983.tb01532.x","volume":"15","author":"LL Gustafsson","year":"1983","unstructured":"Gustafsson LL, Walker O, Alv\u00e1n G, Beermann B, Estevez F, Gleisner L, et al. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol. 1983;15:471\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"891_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF00547567","volume":"23","author":"A Tulpule","year":"1982","unstructured":"Tulpule A, Krishnaswamy K. Effect of food on bioavailability of chloroquine. Eur J Clin Pharmacol. 1982;23:271\u20133.","journal-title":"Eur J Clin Pharmacol"},{"key":"891_CR9","unstructured":"Alliance Pharmaceuticals. Summary of Product Characteristics: Avaclor. https:\/\/www.medicines.org.uk\/emc\/product\/5490\/smpc. Accessed 16 Apr 2020."},{"key":"891_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-016-1181-1","volume":"15","author":"R H\u00f6glund","year":"2016","unstructured":"H\u00f6glund R, Moussavi Y, Ruengweerayut R, Cheomung A, \u00c4bel\u00f6 A, Na-Bangchang K. Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border. Malar J. 2016;15:1\u20139.","journal-title":"Malar J"},{"key":"891_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/BF00542151","volume":"26","author":"M Frisk-Holmberg","year":"1984","unstructured":"Frisk-Holmberg M, Bergqvist Y, Termond E, Domeij-Nyberg B. The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects. Eur J Clin Pharmacol. 1984;26:521\u201330.","journal-title":"Eur J Clin Pharmacol"},{"key":"891_CR12","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1007\/s11095-008-9787-9","volume":"25","author":"S Sahin","year":"2008","unstructured":"Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res. 2008;25:2869\u201377.","journal-title":"Pharm Res"},{"key":"891_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1365-2125.1987.tb03165.x","volume":"24","author":"L Gustafsson","year":"1987","unstructured":"Gustafsson L, Lindstrom B, Grahnen A, Alvan G. Chloroquine excretion following malaria prophylaxis. Br J Clin Pharmacol. 1987;24:221\u20134.","journal-title":"Br J Clin Pharmacol"},{"key":"891_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2165\/00003088-199631040-00003","volume":"31","author":"J Ducharme","year":"1996","unstructured":"Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine: focus on recent advancements. Clin Pharmacokinet. 1996;31:257\u201374.","journal-title":"Clin Pharmacokinet"},{"key":"891_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/0306-3623(82)90110-0","volume":"13","author":"SA Adelusi","year":"1982","unstructured":"Adelusi SA, Salako LA. Kinetics of the distribution and elimination of chloroquine in the rat. Gen Pharmacol. 1982;13:433\u20137.","journal-title":"Gen Pharmacol"},{"key":"891_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0140-6736(83)91770-1","volume":"1","author":"LL Gustafsson","year":"1983","unstructured":"Gustafsson LL, Bergqvist Y, Ericsson O, Larsson M, Rombo L. Pitfalls in the measurement of chloroquine concentration. Lancet. 1983;1:126.","journal-title":"Lancet"},{"key":"891_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1172\/JCI101980","volume":"27","author":"RW Berliner","year":"1948","unstructured":"Berliner RW, Earle DP, Taggart JV, Zubrod CG, Welch WJ, Conan NJ, et al. Studies on the chemotherapy of the human malarias. VI. The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline. J Clin Invest. 1948;27:98\u2013107.","journal-title":"J Clin Invest"},{"key":"891_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-018-2635-4","volume":"18","author":"A Daher","year":"2019","unstructured":"Daher A, Aljayyoussi G, Pereira D, Lacerda MVG, Alexandre MAA, Nascimento CT, et al. Pharmacokinetics\/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine. Malar J. 2019;18:1\u20139.","journal-title":"Malar J"},{"key":"891_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01846-19","volume":"64","author":"J Ursing","year":"2020","unstructured":"Ursing J, Rombo L, Eksborg S, Larson L, Bruvoll A, Tarning J, et al. High-dose chloroquine for uncomplicated plasmodium falciparum malaria is well tolerated and causes similar QT interval prolongation as standard-dose chloroquine in children. Antimicrob Agents Chemother. 2020;64:1\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"891_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-13-1","volume":"13","author":"Q Zhao","year":"2014","unstructured":"Zhao Q, Tensfeldt TG, Chandra R, Mould DR. Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tablets. Malar J. 2014;13:1\u20138.","journal-title":"Malar J"},{"key":"891_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0378-4347(00)86110-1","volume":"272","author":"Y Bergqvist","year":"1983","unstructured":"Bergqvist Y, Domeij-Nyberg B. Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma. J Chromatogr. 1983;272:137\u201348.","journal-title":"J Chromatogr"},{"key":"891_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1365-2125.1983.tb01513.x","volume":"15","author":"O Walker","year":"1983","unstructured":"Walker O, Birkett DJ, Alv\u00e1n G, Gustafsson LL, Sj\u00f6qvist F. Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol. 1983;15:375\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"891_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/clpt.1983.183","volume":"34","author":"LL Gustafsson","year":"1983","unstructured":"Gustafsson LL, Rombo L, Alv\u00e1n G, Bj\u00f6rkman A, Lind M, Walker O. On the question of dose-dependent chloroquine elimination of a single oral dose. Clin Pharmacol Ther. 1983;34:383\u20135.","journal-title":"Clin Pharmacol Ther"},{"key":"891_CR24","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/jmv.25440","volume":"91","author":"Y Han","year":"2019","unstructured":"Han Y, Pham HT, Xu H, Quan Y, Mespl\u00e8de T. Antimalarial drugs and their metabolites are potent Zika virus inhibitors. J Med Virol. 2019;91:1182\u201390.","journal-title":"J Med Virol"},{"key":"891_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.2042-7158.1986.tb04635.x","volume":"38","author":"EE Essien","year":"1986","unstructured":"Essien EE, Ette EI. Effects of chloroquine and didesethylchloroquine on rabbit myocardium and mitochondria. J Pharm Pharmacol. 1986;38:543\u20136.","journal-title":"J Pharm Pharmacol"},{"key":"891_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/BF02976712","volume":"26","author":"K-A Kim","year":"2003","unstructured":"Kim K-A, Park J-Y, Lee J-S, Lim S. Cytochrome P450 2C8 and CYP3A4\/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003;26:631\u20137.","journal-title":"Arch Pharm Res"},{"key":"891_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000187506","volume":"65","author":"P Finielz","year":"1993","unstructured":"Finielz P, Gendoo Z, Chuet C, Guiserix J. Interaction between cyclosporin and chloroquine. Nephron. 1993;65:333.","journal-title":"Nephron"},{"key":"891_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000187007","volume":"62","author":"MR Nampoory","year":"1992","unstructured":"Nampoory MR, Nessim J, Gupta RK, Johny KV. Drug interaction of chloroquine with ciclosporin. Nephron. 1992;62:108\u20139.","journal-title":"Nephron"},{"key":"891_CR29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/jfcm.JFCM_78_19","volume":"26","author":"FY Khan","year":"2019","unstructured":"Khan FY. Imported Plasmodium vivax malaria complicated by reversible myocarditis. J Family Community Med. 2019;26:232\u20134.","journal-title":"J Family Community Med"},{"key":"891_CR30","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/BF00607097","volume":"24","author":"M Frisk-Holmberg","year":"1983","unstructured":"Frisk-Holmberg M, Bergqvist Y, Domeij-Nyberg B. Steady state disposition of chloroquine in patients with rheumatoid disease. Eur J Clin Pharmacol. 1983;24:837\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"891_CR31","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.2165\/00003088-200342150-00004","volume":"42","author":"DR Brocks","year":"2003","unstructured":"Brocks DR, Mehvar R. Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet. 2003;42:1359\u201382.","journal-title":"Clin Pharmacokinet"},{"key":"891_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM198801073180101","volume":"318","author":"B Riou","year":"1988","unstructured":"Riou B, Barriot P, Rimailho A, Baud FJ. Treatment of severe chloroquine poisoning. N Engl J Med. 1988;318:1\u20136.","journal-title":"N Engl J Med"},{"key":"891_CR33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.5694\/j.1326-5377.1978.tb76816.x","volume":"2","author":"WJ Britton","year":"1978","unstructured":"Britton WJ, Kevau IH. Intentional chloroquine overdosage. Med J Aust. 1978;2:407\u201310.","journal-title":"Med J Aust"},{"key":"891_CR34","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1136\/pgmj.67.789.678","volume":"67","author":"G Stiff","year":"1991","unstructured":"Stiff G, Robinson D, Cugnoni HL, Touquet R, Dalton AM. Massive chloroquine overdose: a survivor. Postgrad Med J. 1991;67:678\u20139.","journal-title":"Postgrad Med J"},{"key":"891_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/096032718300200301","volume":"2","author":"AH Stead","year":"1983","unstructured":"Stead AH, Moffat AC. A collection of therapeutic, toxic and fatal blood drug concentrations in man. Hum Toxicol. 1983;2:437\u201364.","journal-title":"Hum Toxicol"},{"key":"891_CR36","first-page":"242","volume":"2","author":"A Jaeger","year":"1987","unstructured":"Jaeger A, Sauder P, Kopferschmitt J, Flesch F. Clinical features and management of poisoning due to antimalarial drugs. Med Toxicol Adverse Drug Exp. 1987;2:242\u201373.","journal-title":"Med Toxicol Adverse Drug Exp"},{"key":"891_CR37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cpt1979253345","volume":"25","author":"M Frisk-Holmberg","year":"1979","unstructured":"Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, Hellstr\u00f6m L, Jansson F. Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics. Clin Pharmacol Ther. 1979;25:345\u201350.","journal-title":"Clin Pharmacol Ther"},{"key":"891_CR38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1542\/peds.27.1.95","volume":"27","author":"HM Cann","year":"1961","unstructured":"Cann HM, Verhulst HL. Fatal acute chloroquine poisoning in children. Pediatrics. 1961;27:95\u2013102.","journal-title":"Pediatrics"},{"key":"891_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0196-0644(05)82141-9","volume":"19","author":"JC Kelly","year":"1990","unstructured":"Kelly JC, Wasserman GS, Bernard WD, Schultz C, Knapp J. Chloroquine poisoning in a child. Ann Emerg Med. 1990;19:47\u201350.","journal-title":"Ann Emerg Med"},{"key":"891_CR40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/BF01709241","volume":"18","author":"GG Collee","year":"1992","unstructured":"Collee GG, Samra GS, Hanson GC. Chloroquine poisoning: ventricular fibrillation following \u2018trivial\u2019 overdose in a child. Intensive Care Med. 1992;18:170\u20131.","journal-title":"Intensive Care Med"},{"key":"891_CR41","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jama.1964.03070120072023","volume":"189","author":"HA Markowitz","year":"1964","unstructured":"Markowitz HA, Mcginley JM. Chloroquine poisoning in a child. JAMA. 1964;189:950\u20131.","journal-title":"JAMA"},{"key":"891_CR42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","volume":"323","author":"E Keyaerts","year":"2004","unstructured":"Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323:264\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"891_CR43","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1128\/AAC.35.10.1953","volume":"35","author":"DE Nix","year":"1991","unstructured":"Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother. 1991;35:1953\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"891_CR44","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1128\/AAC.48.5.1441-1453.2004","volume":"48","author":"M M\u00fcller","year":"2004","unstructured":"M\u00fcller M, dela Pe\u00f1a A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother. 2004;48:1441\u2013533.","journal-title":"Antimicrob Agents Chemother"},{"key":"891_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/jac\/dkm476","volume":"61","author":"JW Mouton","year":"2008","unstructured":"Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. Tissue concentrations: do we ever learn? J Antimicrob Chemother. 2008;61:235\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"891_CR46","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1128\/AAC.36.7.1412","volume":"36","author":"E Vallee","year":"1992","unstructured":"Vallee E, Azoulay-Dupuis E, Pocidalo JJ, Bergogne-Berezin E. Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. Antimicrob Agents Chemother. 1992;36:1412\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"891_CR47","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1128\/AAC.35.3.406","volume":"35","author":"E Pussard","year":"1991","unstructured":"Pussard E, Lepers JP, Clavier F, Raharimalala L, Le Bras J, Frisk-Holmberg M, et al. Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 1991;35:406\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"891_CR48","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1365-2125.1983.tb02244.x","volume":"16","author":"O Walker","year":"1983","unstructured":"Walker O, Dawodu A, Adeyokunnu A, Salako L, Alvan G. Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria. Br J Clin Pharmacol. 1983;16:701\u20135.","journal-title":"Br J Clin Pharmacol"},{"key":"891_CR49","first-page":"177","volume":"13","author":"LA Salako","year":"2005","unstructured":"Salako LA, Walker O, Iyun AO. Pharmacokinetics of chloroquine in renal insufficiency. Afr J Med Med Sci. 2005;13:177\u201382.","journal-title":"Afr J Med Med Sci"},{"key":"891_CR50","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1365-2125.1982.tb02016.x","volume":"14","author":"S Adelusi","year":"1982","unstructured":"Adelusi S, Dawodu A, Salako L. Kinetics of the uptake and elimination of chloroquine in children with malaria. Br J Clin Pharmacol. 1982;14:483\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"891_CR51","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2125.2007.03050.x","volume":"65","author":"C Obua","year":"2008","unstructured":"Obua C, Hellgren U, Ntale M, Gustafsson LL, Ogwal-Okeng JW, Gordi T, et al. Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Br J Clin Pharmacol. 2008;65:493\u2013501.","journal-title":"Br J Clin Pharmacol"},{"key":"891_CR52","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1365-2125.1988.tb03332.x","volume":"25","author":"G Edwards","year":"1988","unstructured":"Edwards G, Looareesuwan S, Davies AJ, Wattanagoon Y, Phillips RE, Warrell DA. Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. Br J Clin Pharmacol. 1988;25:477\u201385.","journal-title":"Br J Clin Pharmacol"},{"key":"891_CR53","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/infdis\/jiv590","volume":"213","author":"J Ursing","year":"2016","unstructured":"Ursing J, Rombo L, Bergqvist Y, Rodrigues A, Kofoed P-E. High-dose chloroquine for treatment of chloroquine-resistant Plasmodium falciparum malaria. J Infect Dis. 2016;213:1315\u201321.","journal-title":"J Infect Dis"},{"key":"891_CR54","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/00007691-198609000-00008","volume":"8","author":"A Akintonwa","year":"1986","unstructured":"Akintonwa A, Odutola TA, Edeki T, Mabadeje AF. Hemodialysis clearance of chloroquine in uremic patients. Ther Drug Monit. 1986;8:285\u20137.","journal-title":"Ther Drug Monit"},{"key":"891_CR55","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/17425255.2013.799137","volume":"9","author":"DJ Roberts","year":"2013","unstructured":"Roberts DJ, Hall RI. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin Drug Metab Toxicol. 2013;9:1067\u201384.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"891_CR56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1164\/rccm.201510-2114OC","volume":"194","author":"NJ Vet","year":"2016","unstructured":"Vet NJ, Brussee JM, De Hoog M, Mooij MG, Verlaat CWM, Jerchel IS, et al. Inflammation and organ failure severely affect midazolam clearance in critically ill children. Am J Respir Crit Care Med. 2016;194:58\u201366.","journal-title":"Am J Respir Crit Care Med"},{"key":"891_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-5-1","volume":"5","author":"IA Clark","year":"2006","unstructured":"Clark IA, Budd AC, Alleva LM, Cowden WB. Human malarial disease: a consequence of inflammatory cytokine release. Malar J. 2006;5:1\u201332.","journal-title":"Malar J"},{"key":"891_CR58","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17425255.2018.1440287","volume":"14","author":"C Smit","year":"2018","unstructured":"Smit C, De Hoogd S, Br\u00fcggemann RJM, Knibbe CAJ. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol. 2018;14:275\u201385.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"891_CR59","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010814-124354","volume":"55","author":"CAJ Knibbe","year":"2015","unstructured":"Knibbe CAJ, Brill MJE, Van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;55:149\u201367.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"891_CR60","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994","author":"C Wu","year":"2020","unstructured":"Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0994.","journal-title":"JAMA Intern Med"},{"key":"891_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/irv.12618","volume":"13","author":"JAS Moser","year":"2019","unstructured":"Moser JAS, Galindo-Fraga A, Ortiz-Hern\u00e1ndez AA, Gu W, Hunsberger S, Gal\u00e1n-Herrera J-F, et al. Underweight, overweight, and obesity as independent risk factors for hospitalization in adults and children from influenza and other respiratory viruses. Influenza Other Respir Viruses. 2019;13:3\u20139.","journal-title":"Influenza Other Respir Viruses"},{"key":"891_CR62","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2165\/11592890-000000000-00000","volume":"50","author":"S Van Kralingen","year":"2011","unstructured":"Van Kralingen S, Diepstraten J, Peeters MYM, Deneer VHM, van Ramshorst B, Wiezer RJ, et al. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin Pharmacokinet. 2011;50:739\u201350.","journal-title":"Clin Pharmacokinet"},{"key":"891_CR63","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2165\/11598930-000000000-00000","volume":"51","author":"S McLeay","year":"2012","unstructured":"McLeay S, Morrish G, Kirkpatrick C, Green B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51:319\u201330.","journal-title":"Clin Pharmacokinet"},{"key":"891_CR64","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2125.1987.tb03048.x","volume":"23","author":"O Walker","year":"1987","unstructured":"Walker O, Salako LA, Alv\u00e1n G, Ericsson O, Sj\u00f6qvist F. The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br J Clin Pharmacol. 1987;23:295\u2013301.","journal-title":"Br J Clin Pharmacol"},{"key":"891_CR65","first-page":"149","volume":"8","author":"W Charoenchokthavee","year":"2016","unstructured":"Charoenchokthavee W, Panomvana D, Sriuranpong V, Areepium N. Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment. Breast Cancer. 2016;8:149\u201355.","journal-title":"Breast Cancer"},{"key":"891_CR66","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1096","author":"RM Inciardi","year":"2020","unstructured":"Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. https:\/\/doi.org\/10.1001\/jamacardio.2020.1096.","journal-title":"JAMA Cardiol"},{"key":"891_CR67","unstructured":"Woosley R, Heise C, Gallo T, Tate J, Woosley D, Romero K. QTdrugs list. https:\/\/www.CredibleMeds.org. [Accessed 30 Mar 2020]."},{"key":"891_CR68","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.","journal-title":"Cell Discov"},{"key":"891_CR69","unstructured":"Dutch Working Party on Antibiotic Policy (Stichting Werkgroep Antibiotica Beleid, SWAB). Medicamenteuze behandelopties bij pati\u00ebnten met COVID-19 (infecties met SARS-CoV-2). https:\/\/swab.nl\/nl\/covid-19. Accessed 24 Mar 2020."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00891-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00891-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00891-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T22:44:14Z","timestamp":1696027454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00891-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,18]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00891-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,18]]},"assertion":[{"value":"18 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Cornelis Smit, Mariska Y.M. Peeters, John N. van den Anker, and Catherijne A.J. Knibbe have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funding was received for the preparation of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The applied NONMEM control stream and R-code to create the datasets used for the simulations can be found in the ESM.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}